This NDC is on FDA's drug shortage list (posted Jul 18, 2023)
Reported reason: Delay in shipping of the drug
Product Information
VICTOZA 3-PAK 18 MG/3 ML PEN is a brand product labeled by Novo Nordisk, priced at $87.8142 per ML under NDC 00169406013. Its NADAC has been published 655 times since Nov 28, 2013.
FDA first approved this application on Jan 25, 2010. Its Orange Book therapeutic-equivalence code is AP1.
The High Outlier badge above means this manufacturer's average price in the liraglutide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
6 mg/mL
Manufacturer
Novo NordiskNDC
00169406013
Classification
Brand
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
8/19/2026
Active Ingredients
LIRAGLUTIDEApproval Type
New Drug (NDA)
FDA Application
NDA022341FDA Approved
1/25/2010
TE Code
AP1
On Market Since
1/25/2010
Pharmacological Classes
Price Statistics
The NADAC for VICTOZA 3-PAK 18 MG/3 ML PEN has been published 655 times since Nov 28, 2013, and over the history we have for it it has risen 65.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $87.8142 per ML |
|---|---|
| All-time high | $119.6510 (Jan 3, 2024) |
| All-time low | $53.1536 (Nov 28, 2013) |
| 52-week high | $87.9055 |
| 52-week low | $87.4690 |
| Median price | $87.5477 |
| Average price | $91.2541 |
| Largest weekly change | -27.0% (Jan 10, 2024) |
| Weeks tracked | 655 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 64% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of VICTOZA 3-PAK 18 MG/3 ML PEN?
The current National Average Drug Acquisition Cost (NADAC) for VICTOZA 3-PAK 18 MG/3 ML PEN, manufactured by Novo Nordisk, is $87.8142 per ML (NDC 00169406013), effective Aug 19, 2026.
How has the price of VICTOZA 3-PAK 18 MG/3 ML PEN changed over time?
Over the history we have for it, the NADAC for VICTOZA 3-PAK 18 MG/3 ML PEN has risen 65.2%. It has been tracked across 655 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for VICTOZA 3-PAK 18 MG/3 ML PEN?
Since Nov 28, 2013, the NADAC for VICTOZA 3-PAK 18 MG/3 ML PEN has ranged from a low of $53.1536 (Nov 28, 2013) to a high of $119.6510 (Jan 3, 2024), with a median of $87.5477 per ML.
Are there cheaper alternatives to VICTOZA 3-PAK 18 MG/3 ML PEN?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LIRAGLUTIDE 3-PAK 18 MG/3 ML, is $32.0017 per ML — about 64% below VICTOZA 3-PAK 18 MG/3 ML PEN.
Who manufactures VICTOZA 3-PAK 18 MG/3 ML PEN?
VICTOZA 3-PAK 18 MG/3 ML PEN (NDC 00169406013) is labeled by Novo Nordisk, and CMS classifies it as a brand product.
Is VICTOZA 3-PAK 18 MG/3 ML PEN in shortage?
Yes — NDC 00169406013 is currently listed in FDA's drug shortage database (posted Jul 18, 2023). Reported reason: Delay in shipping of the drug.